PRELIMINARY OUTCOMES OF REZŪM WATER VAPOR THERAPY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
Main Article Content
Abstract
Objective: To evaluate the efficacy and safety of Rezūm therapy through the first three clinical cases, with a discussion on the role of Rezūm compared to transurethral resection of the prostate in the current management of benign prostatic hyperplasia.
Methods: A descriptive study of three benign prostatic hyperplasia cases treated with Rezūm therapy, including patient selection criteria, procedural technique, and pre- and post-treatment assessments: international prostate symptom score, quality of life score, post-void residual urine volume, prostate size reduction, complications, and sexual function.
Results: After 3 months of follow-up, all three patients showed significant improvements: international prostate symptom score decreased by 77.8-80%, quality of life improved by 80%, and post-void residual was markedly reduced. Prostate volume decreased on both ultrasound and magnetic resonance imaging after 3 months. The duration of indwelling urinary catheterization ranged from 10 to 14 days. No procedure-related complications were reported. Sexual function was preserved in two patients, the remaining case could not be evaluated due to pre-existing erectile dysfunction.
Conclu
Rezūm, benign prostatic hyperplasia, LUTS, TURP.
sion: Rezūm therapy is a safe, effective, and minimally invasive treatment option for patients with lower urinary tract symptoms/benign prostatic hyperplasia, with the notable advantages of preserving sexual function and enabling rapid recovery. It may serve as a suitable alternative to transurethral resection of the prostate in appropriately selected cases.
Article Details
Keywords
Rezūm, benign prostatic hyperplasia, LUTS, TURP.
References
[2] Westwood J, Geraghty R et al. Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia. Therapeutic Advances in Urology, 2018, 10 (11): 327-333.
[3] Roehrborn C.G. Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations. Reviews in Urology, 2008, 10 (1): 14-25.
[4] Rassweiler J, Teber D et al. Complications of transurethral resection of the prostate (TURP) - incidence, management, and prevention. European Urology, 2006, 50 (5): 969-980.
[5] Darson M.F, Alexander E.E et al. Procedural techniques and multicenter postmarket experience using minimally invasive convective radiofrequency thermal therapy with Rezūm system for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Research and Reports in Urology, 2017, 9: 159-168. doi: 10.2147/RRU.S143679
[6] Dixon C, Cedano E.R et al. Efficacy and safety of Rezūm system water vapor treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology, 2015, 86 (5): 1042-1047.
[7] McVary K.T, Roehrborn C.G. Three-year outcomes of the prospective, randomized controlled Rezūm system study: convective radiofrequency thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Urology, 2018, 111: 1-9. doi: 10.1016/j.urology.2017.10.023.
[8] Alegorides C, Fourmarier M et al. Treatment of benign prostate hyperplasia using the Rezum® water vapor therapy system: results at one year. Progrès en Urologie, 2020, 30 (12): 624-631.
[9] Garden E.B, Shukla D et al. Rezum therapy for patients with large prostates (≥ 80 g): initial clinical experience and postoperative outcomes. World Journal of Urology, 2021, 39 (8): 3041-3048.
[10] Rowaiee R, Akhras A et al. Rezum therapy for benign prostatic hyperplasia: Dubai’s initial experience. Cureus, 2021, 13 (9) : e18083. doi: 10.7759/cureus.18083.